NCT07505095 is a clinical trial of Lecanemab 10 mg/kg in Alzheimer Disease (AD), sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT07505095?

NCT07505095 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT07505095?

Interventions in NCT07505095: Lecanemab 10 mg/kg, Lecanemab 5-10mg/kg.

What condition does NCT07505095 study?

NCT07505095 studies Alzheimer Disease (AD), Alzheimer Dementia, MCI-AD, Early Stage Alzheimer's Disease.

Is NCT07505095 still recruiting?

NCT07505095 is currently not yet recruiting. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT07505095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

Not yet recruiting Last updated 1 April 2026

What this trial tests

trial testing Lecanemab 10 mg/kg in Alzheimer Disease (AD) in 140 participants. Not yet recruiting.

Timeline

30 April 2026

Primary endpoint
30 April 2027

31 January 2028

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	140
Start date	30 April 2026
Primary completion	30 April 2027
Estimated completion	31 January 2028
Sites	1 location across China

Drugs / interventions tested

Lecanemab 10 mg/kg — full drug profile →
Lecanemab 5-10mg/kg

Conditions studied

Alzheimer Disease (AD) — all drugs for Alzheimer Disease (AD) →
Alzheimer Dementia — all drugs for Alzheimer Dementia →
MCI-AD, Early Stage Alzheimer's Disease — all drugs for MCI-AD, Early Stage Alzheimer's Disease →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 50 to 85, any sex, with Alzheimer Disease (AD) or Alzheimer Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lecanemab 10 mg/kg

Trials testing the same drug.

NCT07212062 — The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Diseas · Phase 2 · not yet recruiting
NCT07152418 — Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research · not yet recruiting
NCT01767311 — A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease · Phase 2 · completed

Other recruiting trials for Alzheimer Disease (AD)

Currently open trials in the same condition.

NCT07516119 — Predicting Pre-dementia · recruiting
NCT07127510 — Brain NAD in Alzheimer's Disease · recruiting
NCT07208344 — Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease · EARLY_PHASE1 · recruiting
NCT07146412 — Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistic · NA · recruiting
NCT07180147 — Arlington Longitudinal Optimal Healthy Aging Study (ALOHA) · active not recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07505095 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07505095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing